Investigators
Babak Mahmoudi, Mayuresh Kothare, Rajanikanth Vadigepalli, Gautam Kumar, Charles Horn
1. Define context(s)
aid in clinical trial design
identify/explore new therapies
Primary goal of the model/tool/database
We will develop a virtual simulation environment called CONTOL-CORE for in silico experimentation with the design, analysis, prototyping, deployment, and execution of feedback control architectures for closed-loop stimulation of the peripheral nervous system. The modular algorithm libraries will be designed based on modularity, reusability, flexibility, and integration with O2S2PARC, with building blocks that could accommodate different languages (PYTHON, C, MATLAB). The applicability of the developed simulation platform will be demonstrated for the cardiac and gastrointestinal (GI) systems in simulation by leveraging existing data, models, and the O²S²PARC platform. The two chosen systems cover the two extremes of SPARC-relevant organs in two ways: (1) very slow (GI system) to very fast (cardiac) time scales; and (2) fully data-driven (GI system) to very detailed mechanistic (cardiac) models due to the different levels of basic understanding of these organs. The developed tools will likely to be extensible to other SPARC-relevant organs/functions that lie between these two extremes.
Biological domain of the model
Gastrointestinal system, Cardiac System, potentially other SPARC-relevant organs such as colon and bladder
Structure(s) of interest in the model
Organ-specific functional activity
Spatial scales included in the model
Few centimetres to the full organ
Time scales included in the model
Few seconds (cardiac system) to several minutes (GI system)
2. Data for building and validating the model
| Data for building the model |
Published? |
Private? |
How is credibility checked? |
Current Conformance Level / Target Conformance Level |
| in vitro (primary cells cell, lines, etc.) |
|
|
|
|
| ex vivo (excised tissues) |
|
|
|
|
| in vivo pre-clinical (lower-level organism or small animal) |
Yes. Data are available on cardiac VNS from rats. (Source -- literature) |
Yes, data on gastric EMG is available from Ferrets (Dr. Horn’s Lab, U. of Pittsburgh). |
Data are recorded from the same animal in multiple experimental trials. |
Adequate |
| in vivo pre-clinical (large animal) |
Yes, data on cardiac VNS is available from dogs and pigs (Dr. Ardell's Lab, UCLA) |
|
Data are recorded from the same animal in multiple experimental trials and o |
Adequate |
| Human subjects/clinical |
|
|
|
|
| Other: ________________________ |
Yes. The synthetic data will be generated using a published multi-scale cardiac model. |
|
The published model was validated against the reported data from human subjects under healthy and heart failure physiological conditions. |
Adequate |
| Data for validating the model |
Published? |
Private? |
How is credibility checked? |
Current Conformance Level / Target Conformance Level |
| in vitro (primary cells cell, lines, etc.) |
|
|
|
|
| ex vivo (excised tissues) |
|
|
|
|
| in vivo pre-clinical (lower-level organism or small animal) |
Yes |
Yes |
Data are recorded from the same animal in multiple experimental trials. |
Adequate |
| in vivo pre-clinical (large animal) |
Yes |
|
|
|
| Human subjects/clinical |
|
|
|
|
| Other: ________________________ |
Yes. The synthetic data will be generated using a published multi-scale cardiac model. |
|
The published model was validated against the reported data from human subjects under healthy and heart failure physiological conditions. |
Adequate |
3. Validate within context(s)
|
Who does it? |
When does it happen? |
How is it done? |
Current Conformance Level / Target Conformance Level |
| Verification |
|
|
|
|
| Validation |
We have validated our cardiac and GI models, both physiological and data-driven, using published experimental data as well as simulated data. |
During the development of physiological and data-driven modeling |
Models have been validated either using the physiological data (e.g. heart rate) reported in the literature in response to VNS or simulated data (synthetic data generated from physiological models to develop data-driven models). |
Comprehensive |
| Uncertainty quantification |
We will do. |
Throughout the development of the modular algorithm libraries for dynamic modeling and analysis and closed-loop control. |
Since no model is ever perfect, we will perform rigorous robustness analysis to assess the impact of model uncertainty on the closed-loop performance. We will develop information-theoretic metric to quantify the uncertainty in our developed generative models. |
Adequate |
| Sensitivity analysis |
|
|
|
|
| Other:__________ |
|
|
|
|
| Additional Comments |
|
|
|
|
4. Limitations
| Disclaimer statement (explain key limitations) |
Who needs to know about this disclaimer? |
How is this disclaimer shared with that audience? |
Current Conformance Level / Target Conformance Level |
| Since we will develop low-dimensional dynamical models that can be used in designing closed-loop control strategies, our central assumption is the existence of low-dimensional latent dynamical states of organ functions from which we can reconstruct the observed spatiotemporal dynamics subject to vagus nerve stimulations. |
Users who are going to use our CONTROL-CORE libraries in designing vagus nerve stimulation parameters. |
A list of limitations will be provided with each report/publication from each model/system run and stated in the accompanying documentation. |
Extensive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5. Version control
| Current Conformance Level / Target Conformance Level |
| Extensive |
|
Naming Conventions? |
Repository? |
Code Review? |
| individual modeler |
|
GitHub, O2S2PARC |
|
| within the lab |
|
|
|
| collaborators |
|
|
Reimplementation of the code to reproduce the results. |
6. Documentation
|
Current Conformance Level / Target Conformance Level |
| Code commented? |
Extensive |
| Scope and intended use described? |
Extensive |
| User’s guide? |
Extensive |
| Developer’s guide? |
Extensive |
7. Dissemination
| Current Conformance Level / Target Conformance Level |
| Adequate |
| Target Audience(s): |
“Inner circle” |
Scientific community |
Public |
| Simulations |
Reports |
Publications, Github, SPARC portal |
Github, SPARC portal |
| Models |
Reports |
Publications, Github, SPARC portal |
Github, SPARC portal |
| Software |
O2S2PARC |
O2S2PARC |
|
| Results |
Reports |
Publications |
Publications |
| Implications of results |
Reports |
Publications |
Publications |
8. Independent reviews
| Current Conformance Level / Target Conformance Level |
| Adequate |
| Reviewer(s) name & affiliation: |
|
| When was review performed? |
|
| How was review performed and outcomes of the review? |
|
9. Test competing implementations
| Current Conformance Level / Target Conformance Level |
| Adequate |
|
Yes or No (briefly summarize) |
| Were competing implementations tested? |
No, we are in the phase of testing our closed-loop designs on ControlCore platform. |
| Did this lead to model refinement or improvement? |
|
11. (optional) Additional information to support items 1-10
We will use the containerization platform Docker to host algorithm libraries and develop a set of microservices (available as containers on O2S2PARC) to provide standard interfaces to pull data and/or existing models from repositories and make them accessible for simulating the closed-loop peripheral stimulation control systems. To facilitate “easy-to-use” CONTROL-CORE platform, we will use the Flowchart format in the O2S2PARC platform to develop both graphic-user-interface (GUI) and a coding interface that will enable users from a variety of backgrounds and from multiple sites to effectively utilize the platform in a collaborative fashion.